{"disease":{"id":"pancreatic-adenocarcinoma-resectable","name":"pancreatic adenocarcinoma resectable"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06388967","title":"Pancreatic Cancer Detection Consortium","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06966440","title":"Adjuvant Pancreatic Therapy Guided by MRD","phase":"NA","overall_status":"RECRUITING","enrollment_count":856,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07252232","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT03750669","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05083247","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":256,"lead_sponsor_name":"Erasme University Hospital","has_results":false},{"nct_id":"NCT04423731","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT05524090","title":"PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":223,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT04858334","title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02562716","title":"S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT05518903","title":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04821284","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Flemming Forsberg","has_results":false},{"nct_id":"NCT03063554","title":"EUS BD vs ERCP TP for Pancreatic Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT07080021","title":"A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":119,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05181605","title":"Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":116,"lead_sponsor_name":"Instituto de investigación e innovación biomédica de Cádiz","has_results":false},{"nct_id":"NCT04481204","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07022015","title":"Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT04789486","title":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06090916","title":"Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06649474","title":"Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT04986930","title":"mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT04005690","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06595160","title":"Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02336672","title":"EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03368963","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02495896","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06214533","title":"Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT01053013","title":"Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"The Rogosin Institute","has_results":true},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07189195","title":"TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT03095781","title":"Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT07269626","title":"PULSAR in Systemic Therapy for Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05685602","title":"CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07480928","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT01783171","title":"Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05078775","title":"Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Faeth Therapeutics","has_results":false},{"nct_id":"NCT03772756","title":"EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT05624918","title":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Ashish Manne","has_results":false},{"nct_id":"NCT06423326","title":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04915417","title":"Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03291938","title":"IACS-010759 in Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04514497","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04887805","title":"Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03970252","title":"Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03410030","title":"Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"HonorHealth Research Institute","has_results":false},{"nct_id":"NCT06381154","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04484909","title":"NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}